Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome

Figure 2 Liver enzyme changes in 20 patients with non-alcoholic steatohepatitis during the 12 mo of rosuvastatin (10 mg/d) monotherapy. The reduction in serum alanine transaminase (ALT), aspartate transaminase (AST) and γ-glutamyl transpeptidase (GGT) levels became statistical significant by the 3^rd month of treatment (ANOVA for the 12 mo period P < 0.001) and for alkaline phosphatase (ALP) by the 6^th mo of treatment (ANOVA for the 12 mo period P = 0.01).